India's Cipla in drug supply talks with GSK, Teva

HONG KONG, Jan 4 (Reuters) - Indian drug maker Cipla Ltd CIPL.BO is in talks with multinational and leading generic drug companies, including GlaxoSmithKline GSK.L and Israel's Teva TEVA.TA, to supply generic drugs, its chairman said on Monday.

Cipla, India’s second-largest pharmaceutical company by market value, had been in negotiations with GlaxoSmithKline for six months, Yusuf Hamied, also managing director, told Reuters in an interview.

“It may be specifically for one or two products -- it is not a down-the-line drug deal,” said Hamied. He also said there was “not a chance” that Cipla was in talks to sell a stake to a partner company.

In December 2009, Cipla said it was in talks with a host of global drugmakers including Pfizer Inc PFE.N to supply generic products. [ID:nBOM377963]

Hamied confirmed reports in December 2009 that Cipla was in supply talks with German drugmaker Boehringer Ingelheim. (Reporting by Farah Master; Editing by Chris Lewis)


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.